Danaher Corporation
General ticker "DHR" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $144.3B (TTM average)
Danaher Corporation does not follow the US Stock Market performance with the rate: -2.4%.
Estimated limits based on current volatility of 1.2%: low 226.45$, high 231.82$
Factors to consider:
- Earnings expected soon, date: 2026-10-21 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-09-30, amount 0.40$ (Y0.70%)
- Total employees count: 60000 (-4.8%) as of 2025
- China accounted for 10.7% of revenue in the fiscal year ended 2025-12-31
- US accounted for 40.6% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Economic downturns and volatility, Supply chain disruptions, Regulatory and compliance, Cybersecurity threats, Product defects
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [215.12$, 282.71$]
- 2026-12-31 to 2027-12-31 estimated range: [233.08$, 304.11$]
Financial Metrics affecting the DHR estimates:
- Positive: with PPE of 29.5 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 19.09
- Positive: 2.37 < Operating cash flow per share per price, % of 3.94
- Positive: 3.48 < Return on assets ratio (scaled to [-100,100]) of 4.13
- Positive: -1.23 < Investing cash flow per share per price, % of -0.73
- Positive: -16.84 < Industry operating profit margin (median), % of -16.21
- Negative: negative Industry operating cash flow (median)
Short-term DHR quotes
Long-term DHR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $23,890.00MM | $23,875.00MM | $24,568.00MM |
| Operating Expenses | $18,688.00MM | $19,012.00MM | $19,878.00MM |
| Operating Income | $5,202.00MM | $4,863.00MM | $4,690.00MM |
| Non-Operating Income | $-158.00MM | $-217.00MM | $-457.00MM |
| Interest Expense | $286.00MM | $278.00MM | $265.00MM |
| R&D Expense | $1,503.00MM | $1,584.00MM | $1,598.00MM |
| Income(Loss) | $5,044.00MM | $4,646.00MM | $4,233.00MM |
| Taxes | $823.00MM | $747.00MM | $633.00MM |
| Other Income(Loss) | $543.00MM | $0.00MM | $14.00MM |
| Net Income(Loss)* | $4,764.00MM | $3,899.00MM | $3,614.00MM |
| Stockholders Equity | $53,486.00MM | $49,543.00MM | $52,534.00MM |
| Inventory | $2,594.00MM | $2,330.00MM | $2,489.00MM |
| Assets | $84,488.00MM | $77,542.00MM | $83,464.00MM |
| Operating Cash Flow | $7,164.00MM | $6,688.00MM | $6,416.00MM |
| Capital expenditure | $1,383.00MM | $1,392.00MM | $1,156.00MM |
| Investing Cash Flow | $-7,081.00MM | $-1,981.00MM | $-1,196.00MM |
| Financing Cash Flow | $-273.00MM | $-8,385.00MM | $-2,961.00MM |
| Earnings Per Share** | $6.47 | $5.33 | $5.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.